AMG.DE - Amgen Inc.

XETRA - XETRA Delayed price. Currency in EUR
149.38
+0.35 (+0.23%)
As of 1:17PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close149.03
Open151.91
Bid149.38 x 20000
Ask150.17 x 9000
Day's range149.30 - 151.91
52-week range134.40 - 161.45
Volume585
Avg. volume1,150
Market cap100.097B
Beta1.20
PE ratio (TTM)48.94
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.48 (3.00%)
Ex-dividend date2018-05-16
1y target estN/A
  • The Wall Street Journal7 hours ago

    New Migraine Drugs Offer Hope to Sufferers

    Lisa DeLeonardo set a Google alert so she would know exactly when the first in a new class of migraine drugs was approved. It happened Thursday, when the U.S. Food and Drug Administration approved Amgen and Novartis’ application for erenumab, whose brand name is Aimovig. It’s an injectable drug touted as the first treatment designed specifically to prevent migraines, and is expected to be available to patients within a week for an annual price of $6,900.

  • Company News For May 21, 2018
    Zacks21 hours ago

    Company News For May 21, 2018

    Companies in the news are: PYPL,AMGN,TTD,CBS

  • Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod
    Zacks22 hours ago

    Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod

    Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.

  • Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst
    CNBC4 days ago

    Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

    Aimovig from Amgen and Novartis could become a $1 billion to $2 billion business in five years, say one Wall Street analyst.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks4 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
    Zacks4 days ago

    Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

    Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.

  • Amgen Stock Rises over 2% on Drug Approvals
    Market Realist4 days ago

    Amgen Stock Rises over 2% on Drug Approvals

    On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

  • BlueBird Bio Stock Jumps over 6% on May 17
    Market Realist4 days ago

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.

  • MarketWatch4 days ago

    FDA approves anti-migraine drug from Novartis, Amgen

    Shares of drugmakers Amgen Inc. and Novartis AG rose in after-hours trading Thursday after jointly announcing FDA approval of Aimovig, a first-of-its-kind treatment for migraines. In a statement, Novartis said the Federal Drug Administration approved Aimovig's use for the preventive treatment of migraines in adults. "Aimovig is the first therapy of its kind targeting the CGRP receptor, and has demonstrated robust efficacy across the spectrum of migraine," Novartis Chief Executive Paul Hudson said in the statement.

  • US approves 1st drug developed to prevent chronic migraines
    Associated Press4 days ago

    US approves 1st drug developed to prevent chronic migraines

    TRENTON, N.J. (AP) — U.S. regulators Thursday approved the first drug designed to prevent chronic migraines.

  • Forbes5 days ago

    FDA Approves Amgen's Migraine Drug

    The U.S. Food and Drug Administration has approved Amgen’s erenumab (which it’s calling Aimovig) to prevent migraines. “We feel pretty strongly this is a huge opportunity to help patients with a targeted, migraine specific medication that’s broadly efficacious, and can be administered in a patient-friendly way,” said Rob Lenz, VP, development at Amgen who lead the development of Aimovig. Amgen is commercializing Aimovig with Novartis in the U.S.

  • Amgen's Just-Approved Migraine Drug Will Cost $6,900 a Year
    Bloomberg5 days ago

    Amgen's Just-Approved Migraine Drug Will Cost $6,900 a Year

    Amgen Inc. will charge a lower-than-expected $6,900 a year for a novel migraine treatment that investors hope will become the biotechnology giant’s next blockbuster. The Food and Drug Administration approved the drug, which will be marketed under the brand name Aimovig, on Thursday. Amgen’s pricing plans for Aimovig have been closely watched amid a wider U.S. debate over high prescription costs.

  • Immunomedics Announces Positive Phase 2 Results
    Market Realist5 days ago

    Immunomedics Announces Positive Phase 2 Results

    Today, Immunomedics (IMMU) announced positive results from a Phase 2 trial evaluating its investigational antibody drug conjugate (or ADC) sacituzumab govitecan in patients suffering from estrogen receptor-positive (or ER+)/human epidermal growth factor receptor 2-negative (or HER2-) metastatic breast cancer who have previously received at least two therapies. The investigational ADC therapy demonstrated an overall response rate of 31% in these heavily pretreated patients. Immunomedics plans to file its first biologics license application with the FDA later this month for the approval of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer (mTNBC).

  • Why Spectrum Pharmaceuticals, Inc. Is Up Big Today
    Motley Fool5 days ago

    Why Spectrum Pharmaceuticals, Inc. Is Up Big Today

    Shares jumped after the company shared new details from an important phase 3 study. Here's what investors need to know.

  • Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data
    Zacks5 days ago

    Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data

    Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.

  • Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
    Zacks6 days ago

    Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar

    Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.

  • Eli Lilly's Cluster Headache Candidate Succeeds in Phase III
    Zacks6 days ago

    Eli Lilly's Cluster Headache Candidate Succeeds in Phase III

    Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.

  • An Update on Teva’s Highly Anticipated Migraine Drug
    Market Realist7 days ago

    An Update on Teva’s Highly Anticipated Migraine Drug

    During Teva’s (TEVA) 1Q18 earnings release on May 3, the company provided an update on the approval and launch of its anti-CGRP (calcitonin gene-related peptide) monoclonal antibody Fremanezumab, a preventive migraine treatment. The company stated that it now doesn’t expect to get FDA (U.S. Food and Drug Administration) approval for Fremanezumab in mid-June as it had earlier estimated. The reason that Teva doesn’t expect approval in June is that Celltrion, which is Teva’s API (active pharmaceutical ingredients) supplier of Fremanezumab, got a warning letter from the FDA in 2017.

  • Better Buy: Amgen Inc. vs. Biogen Inc.
    Motley Fool7 days ago

    Better Buy: Amgen Inc. vs. Biogen Inc.

    Find out which biotech stock stands tallest after a head-to-head matchup.

  • Bloomberg8 days ago

    Wall Street Is More Optimistic on Amgen's Next Blockbuster Drug

    For Amgen Inc., the launch of its next would-be blockbuster medicine may be a chance to avoid pitfalls of the past. After sales of heart drug Repatha finally showed signs of traction in last month’s quarterly earnings, investors are focusing on Amgen’s first-in-class migraine therapy as the stock seeks to recover from a rough few months for mature biotech companies. Amgen and its partner Novartis AG are due to hear by May 17 from U.S. regulators about Aimovig.

  • Forbes8 days ago

    The Trump Plan To Reduce Prescription Drug Prices Will Have A Major Impact

    MAY 11: U.S. President Donald Trump listens to Health and Human Services Secretary Alex Azar deliver remarks during an announcement about drug prices in the Rose Garden at the White House May 11, 2018 in Washington, DC. Trump announced a 'blueprint' for lowering the cost of perscription medications. On Friday, in the White House Rose Garden, President Trump announced a comprehensive new effort to lower drug prices.

  • How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?
    Market Realist13 days ago

    How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?

    In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17, which reflected a ~20% rise on a YoY (year-over-year) basis.

  • How Did Regeneron Pharmaceuticals Perform in 1Q18?
    Market Realist13 days ago

    How Did Regeneron Pharmaceuticals Perform in 1Q18?

    Regeneron Pharmaceuticals (REGN) reported its 1Q18 earnings results on May 3. It generated revenue of $1.5 billion in the quarter compared to $1.3 billion in 1Q17, which reflected a ~15% rise on a YoY (year-over-year) basis and a ~4% fall quarter-over-quarter.

  • A Overview of Merck’s Diabetes Products in 1Q18
    Market Realist13 days ago

    A Overview of Merck’s Diabetes Products in 1Q18

    Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.

  • A Performance Review and Analysts’ Ratings for Celgene in May
    Market Realist13 days ago

    A Performance Review and Analysts’ Ratings for Celgene in May

    In 1Q18, Celgene’s (CELG) Idhifa generated revenue of $14 million. Celgene and bluebird bio will commercialize the drug in the US market and share 50% of US expenditure and profits. Of the 31 analysts tracking Celgene (CELG) in May, seven analysts have recommended “strong buys,” while nine have recommended “buys” on its stock.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes